ADAM-17: a novel therapeutic target for triple negative breast cancer.
McGowan, P M Mullooly, M Caiazza, F Sukor, S Madden, S F Maguire, A A Pierce, A McDermott, E W Crown, J O'Donovan, N
McGowan, P M
Mullooly, M
Caiazza, F
Sukor, S
Madden, S F
Maguire, A A
Pierce, A
McDermott, E W
Crown, J
O'Donovan, N
Advisors
Editors
Other Contributors
Date
2013-02
Date Submitted
Keywords
BREAST CANCER
Other Subjects
CELL BIOLOGY
Subject Mesh
ADAM Proteins
Breast Neoplasms
Cell Line, Tumor
Cell Proliferation
Cell Survival
Female
Humans
Molecular Targeted Therapy
Phosphorylation
RNA, Messenger
Receptor, Epidermal Growth Factor
Receptor, erbB-2
Receptors, Estrogen
Receptors, Progesterone
Signal Transduction
Transforming Growth Factor alpha
Breast Neoplasms
Cell Line, Tumor
Cell Proliferation
Cell Survival
Female
Humans
Molecular Targeted Therapy
Phosphorylation
RNA, Messenger
Receptor, Epidermal Growth Factor
Receptor, erbB-2
Receptors, Estrogen
Receptors, Progesterone
Signal Transduction
Transforming Growth Factor alpha
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
Validated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2 [i.e., those with triple-negative (TN) disease]. ADAM-17 is a protease involved in the activations of several ligands that bind to and promotes intracellular signalling from the EGFR/HER family of receptors.
Language
en
ISSN
1569-8041
eISSN
ISBN
DOI
10.1093/annonc/mds279
PMID
22967992